Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without Osteoporosis

@article{Artuso2016LongitudinalEO,
  title={Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without Osteoporosis},
  author={A. Artuso and C. Caimmi and G. Tripi and O. Viapiana and M. Bonifacio and L. Idolazzi and I. Gavioli and D. Gatti and R. Zanotti and M. Rossini},
  journal={Calcified Tissue International},
  year={2016},
  volume={100},
  pages={40-46}
}
Systemic Mastocytosis has been long identified as a potential cause of osteoporosis; nevertheless, data regarding longitudinal variation of bone mineral density (BMD) in patients with indolent systemic mastocytosis (ISM) are missing . We studied BMD variation at lumbar spine and proximal hip after 30-month (±6 months) follow-up in a large cohort of patients (83) with ISM without osteoporosis, supplementated with vitamin D and/or calcium when needed. We also analyzed the correlation between… Expand

References

SHOWING 1-10 OF 27 REFERENCES
Rapid Bone Loss Is Associated with Increased Levels of Biochemical Markers
  • P. Ross, W. Knowlton
  • Medicine, Biology
  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 1998
Bone complications of mastocytosis: a link between clinical and biological characteristics.
Zoledronic acid in osteoporosis secondary to mastocytosis.
Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis.
Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis
Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes
Bone involvement and osteoporosis in mastocytosis.
Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis
...
1
2
3
...